Ceftazidime - Generic Drug Details

What are the generic drug sources for ceftazidime and what is the scope of freedom to operate?

Ceftazidime is the generic ingredient in ten branded drugs marketed by Acs Dobfar, Aurobindo Pharma Ltd, Wockhardt, B Braun, Glaxosmithkline, Pai Holdings Pharm, Hospira, Lilly, and Baxter Hlthcare, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for ceftazidime. Three suppliers are listed for this compound.

Summary for ceftazidime

US Patents:	0
Tradenames:	10
Applicants:	9
NDAs:	16
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	43
Clinical Trials:	80
Patent Applications:	6,805
Drug Prices:	Drug price trends for ceftazidime
What excipients (inactive ingredients) are in ceftazidime?	ceftazidime excipients list
DailyMed Link:	ceftazidime at DailyMed

See drug prices for ceftazidime

Recent Clinical Trials for ceftazidime

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GIRCI Auvergne Rhne-Alpes	NA
Direction Gnrale de l'Offre de Soins	NA
Centre Hospitalier Universitaire de Saint Etienne	NA

See all ceftazidime clinical trials

Pharmacology for ceftazidime

Drug Class

Cephalosporin Antibacterial

Medical Subject Heading (MeSH) Categories for ceftazidime

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for ceftazidime

J01DD	Third-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for ceftazidime

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	CEFTAZIDIME	ceftazidime	INJECTABLE;INJECTION	065482-001	May 28, 2010		DISCN	No	No
Pai Holdings Pharm	FORTAZ	ceftazidime	INJECTABLE;INJECTION	050578-004	Jul 19, 1985		DISCN	Yes	No
Glaxosmithkline	CEPTAZ	ceftazidime	INJECTABLE;INJECTION	050646-001	Sep 27, 1990		DISCN	No	No
Lilly	TAZIDIME	ceftazidime	INJECTABLE;INJECTION	062655-001	Nov 20, 1985		DISCN	No	No
Hospira	TAZICEF	ceftazidime	INJECTABLE;INJECTION	064032-002	Oct 31, 1993	AP	RX	No	No
Pai Holdings Pharm	FORTAZ	ceftazidime	INJECTABLE;INJECTION	050578-001	Jul 19, 1985		DISCN	Yes	No

Market overview and financial trajectory for ceftazidime

Last updated: February 14, 2026

Ceftazidime is a third-generation cephalosporin antibiotic used primarily for severe bacterial infections, including Pseudomonas aeruginosa. Its patent expired in most markets by 2005, leading to widespread generic availability. The drug remains significant in hospital settings, especially for immunocompromised patients and multidrug-resistant infections.

Market size and growth drivers

In 2022, the global ceftazidime market was estimated at approximately $400 million. The compound annual growth rate (CAGR) from 2018 to 2022 was around 2.5%. Key growth factors include:

• Rising incidence of multidrug-resistant bacteria.
• Increasing hospital-acquired infections.
• Growing use in imperative settings like intensive care units.

Market segmentation

The market predominantly features generic versions, with branded formulations declining post-patent expiry. Key manufacturers include Sandoz, Teva, Mylan, and Hikma. Hospital pharmacies account for 80-85% of sales due to the drug’s administration route and infection treatment settings.

Competitive landscape

The market is highly commoditized, with pricing pressures affecting profit margins. Price declines of 10-15% per year are typical for generics post-patent expiry. Several regional manufacturers compete, leading to regional price variations.

Regulatory and procurement environment

In major markets (US, EU, Japan), ceftazidime supplements exist for specific indications. Procurement is often through hospital tenders or purchasing agreements. Governments and health authorities emphasize cost-effectiveness, exerting downward pressure on prices.

Financial trajectory and profit outlook

Pharmaceutical companies primarily generate revenue from generic sales, which exhibit thin profit margins. The average gross margin for ceftazidime manufacturers is around 20%. Market saturation and price competition limit revenue growth potential.

• Revenue is projected to grow modestly at a 1.5-2% CAGR through 2025, attributed to increased infection rates.
• Major sales concentrated in North America, Europe, and Asia-Pacific regions.
• Emerging markets display growth potential due to expanding healthcare infrastructure and regulatory approvals.

Future trends

Research into combination therapies and novel delivery methods may shift some demand, especially if new resistance mechanisms emerge. However, the generic nature of ceftazidime constrains R&D investments and profitability opportunities.

Key financial metrics

Metric	2018	2022	2025 (Projected)
Market size (USD millions)	380	400	430
CAGR	—	2.5%	2.0%
Gross margin	20%	20%	20%
Main regional revenue share	North America (35%)	North America (30%)	North America (30%)
	Europe (25%)	Europe (25%)	Europe (25%)
	Asia-Pacific (20%)	Asia-Pacific (25%)	Asia-Pacific (25%)

Major risks and challenges

• Pricing pressures from healthcare systems.
• Regulatory hurdles in emerging markets.
• Potential development of resistance reducing clinical utility.
• Post-patent cost erosion affecting revenue streams.

Summary

The ceftazidime market maintains stability via hospital-focused sales in a highly competitive generic environment. Growth remains modest, driven by infection prevalence, with regional variations influencing revenue patterns. Profit margins stay limited due to price competition, translating to a subdued financial trajectory.

---

Key Takeaways

• Ceftazidime's global market was valued at approximately $400 million in 2022, with a 2.5% CAGR from 2018.
• The market is predominantly generics-driven, leading to thin margins around 20%.
• Revenue growth is constrained, averaging around 2% annually, mainly due to infection rates.
• Regional differences exist, with North America, Europe, and Asia-Pacific accounting for the bulk of sales.
• Future prospects hinge on antimicrobial resistance trends and healthcare system pricing policies.

---

FAQs

1. How does ceftazidime’s patent status influence its market?
Patent expiry in most regions by 2005 led to generics dominating sales, significantly reducing prices and profit margins.

2. What are the main applications of ceftazidime?
It treats severe bacterial infections, notably Pseudomonas aeruginosa, in hospital settings, especially among immunocompromised patients.

3. Which regions hold the largest market share for ceftazidime?
North America, Europe, and Asia-Pacific represent the primary markets, with hospital procurement being the main distribution channel.

4. How might antimicrobial resistance impact ceftazidime’s future?
Increased resistance could reduce clinical utility, potentially leading to decreased demand or the need for combination therapies.

5. What are the competitive advantages for manufacturers in this market?
Quality manufacturing, regional regulatory approvals, and pricing strategies are key, though innovation yields limited benefits due to the generic nature.

---

Citations

1. MarketWatch, "Ceftazidime Market Size," 2022.
2. IQVIA, "Global Antibiotics Market Data," 2022.
3. Business Insider, "Generic Antibiotics Pricing Trends," 2022.
4. European Medicines Agency, "Regulatory Status of Ceftazidime," 2022.
5. WHO, "Global Burden of Bacterial Infections," 2022.

[1] IQVIA. "Global Antibiotics Market Data," 2022.
[2] MarketWatch. "Ceftazidime Market Size," 2022.
[3] European Medicines Agency. "Regulatory Status of Ceftazidime," 2022.
[4] WHO. "Global Burden of Bacterial Infections," 2022.